BIM
PGNX

BlackRock Investment Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

BlackRock Investment Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$2.36M Sell
272,710
-516
-0.2% -$3.81K ﹤0.01% 2119
2016
Q3 		$1.73M Buy
273,226
+12,359
+5% +$74.7K ﹤0.01% 2270
2016
Q2 		$1.1M Buy
260,867
+13,853
+6% +$66.9K ﹤0.01% 2552
2016
Q1 		$1.08M Buy
247,014
+2,773
+1% +$12.3K ﹤0.01% 2435
2015
Q4 		$1.5M Buy
244,241
+148
+0.1% +$970 ﹤0.01% 2284
2015
Q3 		$1.4M Sell
244,093
-2,900
-1% -$22.3K ﹤0.01% 2342
2015
Q2 		$1.84M Buy
246,993
+22,758
+10% +$138K ﹤0.01% 2306
2015
Q1 		$1.34M Buy
224,235
+1,312
+0.6% +$8.26K ﹤0.01% 2322
2014
Q4 		$1.69M Sell
222,923
-2,884
-1% -$17.3K ﹤0.01% 2160
2014
Q3 		$1.17M Buy
225,807
+3,257
+1% +$16.2K ﹤0.01% 2409
2014
Q2 		$959K Buy
222,550
+24,173
+12% +$92.3K ﹤0.01% 2638
2014
Q1 		$811K Buy
198,377
+26,895
+16% +$138K ﹤0.01% 2662
2013
Q4 		$914K Sell
171,482
-2,742
-2% -$12.1K ﹤0.01% 2573
2013
Q3 		$875K Buy
174,224
+32,623
+23% +$177K ﹤0.01% 2541
2013
Q2 		$632K Buy
+141,601
New +$635K ﹤0.01% 2696

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

BlackRock Investment Management's PGNX Position: Q4 2016 in Review

BlackRock Investment Management reduced its Progenics Pharmaceuticals Inc (PGNX) stake by 0.19% in Q4 2016, selling an estimated $3.81K and leaving 272,710 shares worth $2.36M. The position accounts for ﹤0.01% of the portfolio, ranked #2119.

BlackRock Investment Management first reported a position in PGNX in Q2 2013 and has held it in 15 quarters since. 126 funds tracked by Wall St. Rank hold PGNX as of Q4 2016.

  • BlackRock Investment Management held 272,710 shares of Progenics Pharmaceuticals Inc worth $2.36M as of Q4 2016.
  • BlackRock Investment Management sold 516 Progenics Pharmaceuticals Inc shares in Q4 2016, an estimated $3.81K.
  • Progenics Pharmaceuticals Inc made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #2119 holding.
  • BlackRock Investment Management first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and has held it in 15 quarters since.
  • 126 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.